Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Cytosorbents | 23.04 Mn | 18.24 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.24% |
| Dec 31, 2025 | -51.99% |
| Sep 30, 2025 | -30.43% |
| Jun 30, 2025 | 21.79% |
| Mar 31, 2025 | 15.60% |
| Dec 31, 2024 | -13.89% |
| Sep 30, 2024 | 16.66% |
| Jun 30, 2024 | -3.89% |
| Mar 31, 2024 | -5.42% |
| Dec 31, 2023 | -1.55% |
| Sep 30, 2023 | -25.06% |
| Jun 30, 2023 | -1.12% |
| Mar 31, 2023 | -19.69% |
| Dec 31, 2022 | 24.62% |
| Sep 30, 2022 | -42.81% |
| Jun 30, 2022 | -39.35% |
| Mar 31, 2022 | -42.52% |
| Dec 31, 2021 | -13.66% |
| Sep 30, 2021 | -23.97% |
| Jun 30, 2021 | -10.69% |